Viral Vector Quality: No Estimates. Only Evidence

AAV quality depends on more than viral titer alone. Capsid occupancy, aggregation, genome integrity, and product heterogeneity all impact therapeutic performance and regulatory readiness. Explore how CDMS and MALS help scientists generate direct, defensible evidence to support development, manufacturing, and QC decisions.

Characterizing AAVs

Xevo CDMS Characterization of Viruses and Viral-based Therapeutics

Streamlined Characterization of Recombinant AAVs via Charge Detection Mass Spectrometry: Insights from the USP AAV8 Reference Standards

Characterization with Relative Quantitation of Adeno-Associated Viruses (AAVs) using Xevo Charge Detection Mass Spectrometry (CDMS)

Quantifying quality attributes of AAV gene therapy vectors by SEC-MALS-UV-dRI

Real-time monitoring and control of AAV chromatographic enrichment by RT-MALS